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Design, synthesis, and preliminary
evaluation of a potential synthetic opioid rescue
agent
Sidnee L. Hedrick1 , Dan Luo1, Sophia Kaska1, Kumar Kulldeep Niloy1, Karen Jackson1,2, Rupam Sarma1,2,
Jamie Horn1,2, Caroline Baynard3, Markos Leggas1,2, Eduardo R. Butelman3, Mary Jeanne Kreek3† and
Thomas E. Prisinzano1,2*

Abstract
Background: One of the most prominent opioid analgesics in the United States is the high potency agonist fentanyl. It is used in the treatment of acute and chronic pain and as an anesthetic adjuvant. When used inappropriately,
however, ingestion of just a few milligrams of fentanyl or other synthetic opioid can cause opioid-induced respiratory
depression (OIRD), often leading to death. Currently, the treatment of choice for OIRD is the opioid receptor antagonist naloxone. Recent reports, however, suggest that higher doses or repeated dosing of naloxone (due to recurrence
of respiratory depression) may be required to reverse fully fentanyl-induced respiratory depression, rendering this
treatment inadequate. To combat this synthetic opioid overdose crisis, this research aims at identifying a novel opioid
reversal agent with enhanced efficacy towards fentanyl and other synthetic opioids.
Methods: A series of naltrexone analogues were characterized for their ability to antagonize the effects of fentanyl
in vitro utilizing a modified forskolin-induced cAMP accumulation assay. Lead analogue 29 was chosen to undergo
further PK studies, followed by in vivo pharmacological analysis to determine its ability to antagonize opioid-induced
antinociception in the hot plate assay.
Results: A series of potent MOR antagonists were identified, including the highly potent analogue 29
(IC50 = 2.06 nM). Follow-up PK studies revealed 29 to possess near 100% bioavailability following IP administration.
Brain concentrations of 29 surpassed plasma concentrations, with an apparent terminal half-life of ~ 80 min in mice.
In the hot plate assay, 29 dose-dependently (0.01–0.1 mg/kg; IP) and fully antagonized the antinociception induced
by oxycodone (5.6 mg/kg; IP). Furthermore, the dose of 29 that is fully effective in preventing oxycodone-induced
antinociception (0.1 mg/kg) was ineffective against locomotor deficits caused by the KOR agonist U50,488.
Conclusions: Methods have been developed that have utility to identify enhanced rescue agents for the treatment
of OIRD. Analogue 29, possessing potent MOR antagonist activity in vitro and in vivo, provides a promising lead in our
search for an enhanced synthetic opioid rescue agent.
Keywords: Structure–activity relationship, MOR antagonist, Fentanyl, Naltrexone, Antinociceptive activity
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Background
One of the most prominent opioid analgesics in the
United States is the synthetic opioid fentanyl (1) (Fig. 1)
[1]. It is used in the treatment of acute and chronic
pain and as an anesthetic adjuvant [2, 3]. Originally
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Fig. 1 Structures of fentanyl (1), morphine (2), carfentanil (3), naloxone (4a), naltrexone (4b), nalmefene (5), and diprenorphine (6)

synthesized in 1960, fentanyl (1) is approximately 100
times more potent than morphine (2). Intravenous fentanyl has an L
 D50 of 2.91 mg/kg in rats [4]. Among
clinicians, fentanyl rapidly replaced morphine as an anesthetic for surgeries during the 1970s due to its more rapid
onset, higher potency, and limited cardiovascular risks
compared to morphine [5–7]. Currently, there are several
FDA-approved fentanyl analogues for medical and veterinary purposes, including the ultra-potent carfentanil
(3) (approximately 10,000 times more potent than morphine) [8]. Misuse of fentanyl (and fentanyl analogues)
has been estimated to be responsible for 48,000 (out of
a total of 83,335) overdose deaths in the 12 months ending in June 2020, significantly contributing to the national
opioid health crisis [9].
The high potency MOR agonist fentanyl (1) is also
considered an incapacitating agent, a chemical that produces a disabling condition that persists for hours to days
after exposure has occurred [10]. Incapacitating agents
were studied during the Cold War when it was assumed
that incapacitating the enemy would impact them more
because these individuals would not only become unavailable for duty but also because they would consume
more logistical resources relating to their evacuation
[11]. In October 2002, the Russian military used a mysterious “gas” to incapacitate Chechen rebels who had taken

800 hostages at a Moscow theater [12]. Unfortunately,
more than 120 of the hostages in the theater died and
more than 650 of the survivors required hospitalization.
The available evidence strongly suggests that a combination of a potent aerosolized fentanyl derivative, such as
carfentanil (3), and an inhalant anesthetic, such as halothane, was used by the Russian military. Preparation of
medical teams with suitable stores of effective antidotes
would likely have lessened the loss of life.
Chemically, synthetic opioids are highly toxic organic
solids that may be encountered as injectable powders,
liquids, nasal sprays, dermal patches and pills. The particle size of synthetic opioid powders typically ranges from
0.2 to 2.0 μm, and the powders are easily aerosolized,
presenting primarily a respiratory hazard. A secondary
dermal hazard exists if there is direct skin contact with
large bulk amounts of concentrated threat materials [13].
Due to its high potency, ingestion of just a few milligrams
of fentanyl or other synthetic opioid can be deadly to
an opioid-naïve individual or an unsuspecting “recreational” drug user upon acute exposure. Furthermore, first
responders who come in contact with free base fentanyl
analogues are at significant risk for life-threatening toxicities [14].
Currently, there are three FDA-approved opioid antagonists that have potential to reverse the effects of fentanyl
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in humans: naloxone (4a), naltrexone (4b), and nalmefene (5). Naloxone is approved for administration by a
variety of routes, including intravenous, intramuscular,
subcutaneous and intranasal; sublingual and buccal formulations are under development [15]. However, recent
reports suggest that higher doses or repeated dosing of
naloxone (due to recurrence of respiratory depression)
may be required to reverse fully fentanyl-induced respiratory depression [16–18]. These findings have been
recently confirmed in mice where naloxone less readily
reverses respiratory depression by fentanyl compared
with morphine [19].
Recently, diprenorphine (6) was shown to equally
reverse both fentanyl and morphine depression of respiration in mice [19]. Previous studies have also shown
that diprenorphine could be used to reverse the effects of
opioids for which naloxone does not effectively or reliably
reverse the narcotic effects [20]. Presently, diprenorphine
is approved for use in veterinary medicine to reverse
immobilization of wild and exotic animals by etorphine
(reported to be from 1000 to 80,000 times more potent
than morphine depending on the parameter measured)
or carfentanil [21].
The reason for why diprenorphine is more effective at
antagonizing fentanyl than naloxone is not known. One
potential reason for the greater effectiveness of diprenorphine in antagonizing fentanyl-induced respiratory
depression could be the enhanced potency of diprenorphine compared to naloxone [20]. However, it has also
been speculated that the higher lipophilicity and/or an
alternative mode of binding at μ opioid receptors (MORs)
than naloxone may contribute [19].
Collectively, these studies suggest that a synthetic
opioid rescue agent superior to naloxone is needed. An
optimized profile of such a compound would have the
following characteristics: (1) enhanced potency and
lipophilicity; (2) in vivo pharmacokinetics and physiochemical/metabolic properties necessary for multiple
formulations; and (3) few off-target effects and little toxicity. Here, we report our initial work toward identifying
such a rescue agent.

Materials and methods
Synthesis of naltrexone analogues

A series of opiates (7–30) were prepared from commercially available naltrexone hydrochloride (Mallinckrodt, St. Louis, MO) modified in three positions: (1)
the C3-phenol; (2) the 14β-hydroxyl group; and (3) the
C6-keto group. Compounds 7 [22], 8 [23], 9 [24], 10
[25], 11 [25], 12 [25], 13 [26], 15 [27], 17 [28], 18 [29],
19 [28], 23 [30], 24 [31], and 27 [32] were prepared by
previously published procedures. Opiates 14, 16, 20–22,
25, 26, 28–30 were prepared using a general sequence
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of protection, synthetic elaboration, and deprotection.
Experimental details of the synthesis of the series of opiates and their corresponding identification data can be
found in Additional file 1.
Compounds

Morphine sulfate pentahydrate, fentanyl hydrochloride,
oxycodone hydrochloride, naltrexone hydrochloride,
β-funaltrexamine hydrochloride, clocinnamox mesylate,
SNC-80, naltrindole hydrochloride, U50,488H, and Salvinorin A were kindly provided by the National Institute
on Drug Abuse Drug Supply Program. Naloxone hydrochloride dihydrate and nor-binaltorphimine dihydrochloride were purchased from Sigma-Aldrich Chemical
Co. (St. Louis, MO, USA). All other chemicals used were
purchased from commercial sources and are of analytical
grade.
In vitro experiments
Cell lines and cell culture

The cAMP Hunter™ CHO-K1 stably expressing the
human μ opioid receptor (MOR) (OPRM1, catalog #
95-0107C2), human κ opioid receptor (KOR) (OPRK1,
catalog # 95-0088C2), and the human δ opioid receptor (DOR) (OPRD1, catalog # 95-0108C2), were purchased from Eurofins DiscoverX (Fremont, CA) and
maintained in F-12 media supplemented with 10% fetal
bovine serum (Life Technologies, Grand Island, NY), 1%
penicillin/streptomycin/ʟ-glutamine (Life Technologies),
and 800 µg/mL Geneticin (Mirus Bio, Madison, WI). All
cells were grown at 37 °C and 5% C
 O2 in a humidified
incubator.
Forskolin‑induced cAMP accumulation

The agonistic activities of test compound were determined as previously described [33]. Briefly, the aforementioned cAMP Hunter cell lines were detached from
cell culture plates using nonenzymatic cell dissociation
buffer (Life Technologies) and plated at 10,000 cells/well
cell density in 384-well tissue culture plates, and then
incubated at 37 °C overnight. 5 mM Stock solutions of all
test compounds in DMSO (Alfa Aesar, Ward Hill, MA)
were prepared followed by serial dilutions in DMSO
resulting in 10 dose points at a 100× concentration.
Assay buffer [Hank’s Buffered Salt Solution (HBSS, Life
Technologies) and 10 mM HEPES (Life Technologies)]
with forskolin (Eurofins DiscoverX) were used to dilute
the serial dilutions to a working 5× concentration resulting in a concentration of 100 µM forskolin and 5% DMSO
(v/v%). The cells were incubated with the test compounds
at 37 °C for 30 min and the HitHunter cAMP assay for
small molecules assay kit (Eurofins DiscoverX) was used
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according to the manufacturer’s directions for cAMP
detection.
The antagonist activities of test compound were determined in a similar manner except only assay buffer was
used for the dilution of test compounds to 5× working
solutions. The cells were pre-treated and incubated with
vehicle or test compounds for 15 min followed by the
addition of selected agonists at their EC50 or E
 C90 dose
in the presence of forskolin. The cells were further incubated at 37 °C for another 30 min.
Luminescence was quantified using the BioTek Synergy
H1 hybrid reader and Gen5 software (BioTek, Winooski,
VT). Data were blank subtracted with vehicle controls,
normalized to forskolin controls, and analyzed with nonlinear regression by GraphPad Prism 8 (GraphPad, La
Jolla, CA). For the antagonist assay, further normalization to selected reference antagonists (naltrexone (4b) for
MOR and DOR cells, nor-BNI for KOR cells) was used to
determine the I max of test compounds.
Potent and efficacious MOR antagonists were tested
further by Schild analysis [34], which was done by generating fentanyl dose–response curves in the absence
and presence of three doses of test compounds. Data
were analyzed by nonlinear regression with the Gaddum/
Schild EC50 shift function in Prism. Compounds with
Schild slope close to 1 were considered competitive and
pA2 values were calculated (constraining both HillSlope
and SchildSlope to 1). The equilibrium dissociation
constant (Ke) values were calculated as well using the
formula:



Ke = [L]/ A′ /A − 1 ;
[L] is the concentration of antagonist and Aʹ and A are
the EC50 of fentanyl in the presence or absence of a single
dose of the antagonist.
In vivo studies
Pharmacokinetic (PK) study

Adult male C57BL/6J mice were purchased from Jackson
Laboratories (Bar Harbor, ME). The animals were housed
in polyethylene cages and given food and water ad libitum. Animals were administered 29 by intravenous,
oral gavage or intraperitoneal (IV, PO or IP injection).
Two groups of mice (n = 3/group) were sampled three
times each via the saphenous vein. Whole blood samples
were collected into heparinized pipet tips, centrifuged
at 4300×g for 2 min to isolate plasma and transferred
onto dry ice. Plasma samples were stored at − 80 °C until
processing. Separately, for brain biodistribution studies,
five mice per time-point were administered 29 via the IP
route and a single blood sample was collected from each
animal via intracardiac puncture prior to perfusing with
ice-cold saline for 5 min before removing the brain. All
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animal procedures were conducted in accordance with
The Guide for the Care and Use of Laboratory Animals
(National Academic Press, 1996) and approved by the
IACUC (Institutional Animal Care and Use Committee) at the University of Kentucky and at the Rockefeller
University.
Sample processing

Experimental plasma samples were thawed at 37 °C for
3 min and vortex mixed. A 5 µL aliquot of each plasma
sample was added to 5 µL internal standard (100 ng/mL
naltrexone (4b) in methanol:water (1:1, v/v)) and 10 µL
blank mouse plasma. Samples were vortex mixed, then
treated with 4× volume (60 µL) of 0.1% formic acid in
methanol to precipitate proteins. The samples were vortex mixed (5 s) then centrifuged at 13,000×g for 15 min
at 4 °C. The resulting supernatants were collected into
amber HPLC vials fitted with 200 µL glass inserts and
immediately analyzed for analyte content by LC/MS–MS.
Brains were excised and sectioned at the sagittal plane.
Half of the brain from each animal was homogenized
(1:1, w/v) with phosphate buffered saline. Each brain
homogenate aliquot (20 µL) was added to 5 µL of internal standard spiking solution (100 ng/mL naltrexone (4b)
in methanol:water (1:1, v/v)) and vortex mixed. Proteins
were precipitated by addition of 80 µL of 0.1% formic
acid. Samples were vortex mixed (10 s) and stored at
− 20 °C for 20 min prior to centrifugation at 13,000×g
for 15 min at 4 °C. The resulting supernatants were collected into amber HPLC vials fitted with 200 µL glass
inserts and immediately analyzed for analyte content by
LC/MS–MS.
Calibrator, quality control sample preparation

All stock solutions were prepared in methanol at concentration approximately 1 mg/mL for 29, and naltrexone
(4b) (Internal Standard). All working solutions were generated by diluting the stock solutions of all compounds in
methanol:water (1:1, v/v). Calibration curves and quality
control (QC) samples were prepared, and analyses proceeded following assessment of QC concentrations to
determine system suitability.
For the analysis of total amount of 29 in the plasma
samples, calibration curve was generated with 29 drug
spiked to mouse blank plasma. Calibrators (0.25–
1000 ng/mL) were prepared by the addition of 5 µL of
appropriate spiking solution into 100 µL blank plasma
followed by vortex mixing. Quality control samples (0.75,
25, 500, 850 ng/mL) were prepared from an independent second stock in a similar fashion. For the analysis of
29 in brain tissue samples, calibration curve was generated with 29 drug spiked to blank mouse brain tissue
homogenate using a calibration curve (0.5–372 ng/mL)
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and quality control samples (0.75, 13.3, 25, 266 ng/mL).
The limit of quantitation for plasma was 0.4 ng/mL and
for brain tissue 1 ng/mL.

and brain compartments following intraperitoneal
administration.

LC–MSMS analysis

Adult male C57BL/6J mice (Jackson Laboratory, Stock
#00064) were studied for oxycodone-induced thermal
antinociception with the hot plate assay. The apparatus
was a model 39D Hot Plate Analgesia Meter (IITC Life
Science, Woodland Hills, CA) used at a temperature
of 54 °C ± 0.5 °C. Individual mice were placed inside
a cylindrical transparent Plexiglas enclosure (30.6 cm
height × 19.4 cm diameter) which was placed on top of
the hot plate. Prior to experimental study, mice underwent a habituation session, in which they were placed
on the hot plate apparatus at room temperature for two
1-min periods, separated by ~ 10 min. At least 1 day
after room temperature habituation, mice were placed
on the hot plate for two baseline latency determinations
to the 54 °C ± 0.5 °C hot plate temperature. The mouse
was removed from the plate when a withdrawal response
was observed. A response was recorded as a jump or hind
paw lick, with a maximum allowed latency of 45 s, timed
manually by stopwatch. If an animal did not exhibit a
response by the 45 s cutoff, it was removed from the hot
plate, and this value was assigned for data analysis. The
experimenter was “blind” as to the experimental conditions under study (e.g., whether the pretreatment was 29
or vehicle). “Blinding” was carried out by using coded
labels for solutions. The codes were changed across
experiments.
Separate sessions in the same mice were separated at
least 96 h from each other. Each session commenced with
two baseline withdrawal latency determinations, separated by ~ 10 min.
After the baseline determination, the mouse was
injected with vehicle or 29 (IP) at a specified pre-treatment time, and then with vehicle or oxycodone 5.6 mg/
kg (IP). The mouse was tested in a time course procedure
with latencies determined at predetermined times (15-,
30-, 60- and 120-min post oxycodone injection). If at any
of these times the mouse reached the cutoff latency (45 s)
without a nocifensive response, it was removed from the
hot plate and the cutoff value was assigned for data analysis. The cylinder and hot plate were wiped with water
between mice, as needed. The doses and times of oxycodone administration were based on pilot and published
studies [35].

All samples were analyzed for the transitions m/z
382.9 → 323.2 (29), and m/z 342.3 → 270.2 (naltrexone
(4b) ISTD) by LC–MSMS. Analyte and internal standard contained in 4 µL sample injections were eluted
from a Waters XBridge C18 (3.5µ, 4.6 × 150 mm; oven
temp. 40 °C) analytical column with a 0.1% formic acid
in water (Mobile Phase-A): 0.1% formic acid in acetonitrile (Mobile Phase-B) gradient. The flow rate was consistent at 0.7 mL/min while the gradient progressed from
an initial 0.5 min hold at 35% Mobile Phase-B increased
linearly to 90% over 3 min. The 90% Mobile Phase-B was
maintained for 2.5 min before returning to the initial
35% over a 0.1 min linear ramp. The column was equilibrated at 35% organic for 1.9 min. The total run time was
7.5 min. Positive-mode ESI Turbo V
 ® source and MS gas,
temperature and voltage potential settings were based
on optimized parameters determined prior to analysis
using infusions of 1000 ng/mL drug standards in 50:50
mobile phase mixture mixed with LC effluent for a total
0.6 mL/min flow rate. Flow-dependent parameters were:
CUR = 35/ISV = 5500/TEM = 550/GS1 = 65/GS2 = 65/
Horizontal probe position = 7/Vertical probe position = 0.5). The compound dependent parameters for the
m/z 382.9 → 323.2 (29), transition were DP of 30, EP of
10, CAD of 12, CE of 24 and CXP of 15, whereas optimal m/z 342.3 → 270.2 (naltrexone (4b) ISTD) transition
intensity for ISTD was achieved at DP of 30, EP of 10,
CAD of 12, CE of 37 and CXP of 20. Calibrators, quality control samples and experimental sample sequences
consisted of single randomized experimental sample
injections flanked by sets of blanks, and calibrators. A
calibration curve was constructed by weighted (1/x2)
polynomial regression analysis of analyte concentration
to analyte peak area using GraphPad Prism software (Ver
8.4.3).
Pharmacokinetic analyses

All data sets were analyzed using Phoenix WinNonlin (Certara). A 2-compartment mammillary model
was simultaneously fitted to all plasma concentrations
obtained from intravenous, oral, and intraperitoneal
administration of 29. The oral and intraperitoneal bioavailability was also estimated. Parameters were estimated
using population modeling with quasi-random parameter estimation method (QRPEM). Non-compartmental
analyses (NCA) for sparse sampling methods were conducted to estimate the area under the time-concentration
curves (AUC), and the apparent half-life of 29 in plasma

Thermal antinociception studies

Antagonism of 29 against oxycodone‑induced
antinociception

The antagonist potency of 29 was examined with different doses of 29 (0 [vehicle], 0.01, 0.032 and 0.1 mg/kg)
administered 30 min prior to oxycodone (5.6 mg/kg).
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Based on these data, the time course of antagonist effects
of 29 (0.1 mg/kg) was examined by administering this
compound at different times (15, 30, 120, 240 min, and
24 h) prior to oxycodone (5.6 mg/kg).
Antagonism of 29 in preventing locomotor activity deficits
caused by the KOR agonist U50,488

These studies (in C57BL/6J mice from the Jackson
Laboratory) focused on the effectiveness of 29 in preventing decreases in locomotor activity caused by the
KOR agonist U50,488 (10 mg/kg, IP) over 90 min. This
dose and duration of monitoring period was based on
recently published studies [36]. Mice were placed individually in rectangular transparent plastic cages (19.7 cm
width × 41.3 cm length × 20.3 cm height) with bedding
identical to that in the home cage. Each cage was in a
photocell frame with an array of perpendicular photocell
beams (SmartFrame; Kinder Scientific, Poway, CA). Beam
breaks caused by the mouse were quantified through a
computer interface. Mice were habituated to this apparatus for a 60-min session. Consecutive experiments in
the same mice were separated by at least 72 h. Vehicle
or 29 was injected 30 min prior to U50,488 (10 mg/kg).
Immediately after the U50,488 injection, each mouse was
placed in a locomotor activity cage for a 90-min period.
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Results
Chemical synthesis

Analogues 14, 16 and 20–22 were prepared as shown in
Scheme 1. Alkylation of naltrexone (4b) with benzyl bromide in the presence of base, followed by protection of
the ketone with ethylene glycol, gave the known acetal
31 [29]. 14β-O-Alkylation of acetal 31 with dipropyl sulfate or (3-bromoprop-1-en-1-yl)cyclohexane gave ethers
32a and 32b, respectively. Global deprotection with HCl
of 32a gave phenol 20 [37]. Reduction of 32b afforded
phenol 33, which was further deprotected to provide
compound 16. Treatment of acetal 31 with allyl bromide
under basic conditions gave allyl ether 34. Treatment of
34 with HCl gave 14β-O-allyl phenol 21 [37]. Dihydroxylation of 34 with AD-mix-α gave diol 35, which was subsequently deprotected with HCl to afford phenol 22 [38]
Analogue 14 [39] was prepared from naltrexone (4b)
using a sequence of silyl protection, propionic anhydride
esterification, and KF deprotection. Methyl ether analogues 25 and 26 were prepared by benzyl protection,
methylation, and deprotection of α-naltrexol (23) and
β-naltrexol (24) (Scheme 2). Finally, alkenes 28–30 were
prepared according to Scheme 3, utilizing standard Wittig alkenylation to insert C6 olefin functionality [30].
In vitro pharmacology

To validate our fentanyl assay, we examined the effects of
naloxone, naltrexone, and the long-lasting opioid antagoStatistical analyses
nist clocinnamox (CCAM) (Table 1). As expected, naloxThe hot plate locomotor activity data were analyzed one, naltrexone, and CCAM antagonized the actions of
after conversion to percent of maximum possible effect an EC90 dose of fentanyl (2.3 nM). The most potent of
(%MPE) by the standard equation:
these antagonists was naltrexone (IC50 = 8.82 ± 1.53 nM).

 

[ Cutoff latency − Test latency / Cutoff latency − Baseline latency ] × 100%.
The locomotor activity data were analyzed as beam
breaks over 15-min bins. Data were analyzed with 2-way
repeated measures or mixed effects ANOVAs, followed
by appropriate post-hoc tests (GraphPad Prism software).
Drugs

29•oxalate was dissolved daily in sterile water vehicle for
all pharmacodynamic studies. 29•oxalate was dissolved
in saline (1 mg/mL) for pharmacokinetic studies and in
methanol (0.84 mg/mL) for analytical stocks. The MOR
agonist oxycodone HCl (Sigma-Aldrich) was dissolved
in sterile water vehicle. All injections were carried out IP
in a volume of 10 mL/kg body weight. The KOR agonist
U50,488 (Sigma-Aldrich) was dissolved in sterile water.
All injections for antinociception and locomotor studies
were made by the IP route at a volume of 10 mL/kg body
weight.

To further assist in the comparison of ligands, we then
normalized the level of antagonism of each ligand to
naltrexone. Having established our ability to detect μ
antagonism, we next chose to evaluate the actions of
β-funaltrexamine (β-FNA), an irreversible μ selective
antagonist [40]. We found that β-FNA was approximately
threefold less potent than naltrexone (IC50 = 31.02 nM vs.
IC50 = 8.82 nM). However, β-FNA produced a decreased
level of antagonism compared to naltrexone (Imax = 60.0%
vs. Imax = 102.7%). This was not surprising given the covalent nature of β-FNA and the short pretreatment time
(15 min) used. As expected, increasing the pretreatment
time to 2 h with β-FNA led to a full level of antagonism
(Additional file 1). However, we chose to use a short pretreatment time for our subsequent screening efforts.
With our series of epoxymorphinans in hand, we
sought to explore their activity in our fentanyl antagonism assay. Initially, we sought to confirm the importance
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Scheme 1 Synthetic route to C14 analogues 14, 16, and 20–22. Reagents and conditions (a) K2CO3, BnBr, DMF; (b) (CH2OH)2, p-TSA, toluene; (c) NaH,
dipropyl sulfate (32a) or (3-bromoprop-1-en-1-yl)cyclohexane (32b), DMF; (d) conc. HCl, MeOH; (e) NaH, allyl bromide, DMF; (f ) Pd/C, H
 2, THF; (g)
TBDMSCl, imidazole, DMF; (h) Propionic anhydride, Et3N, toluene; (i) KF, MeOH, DCM

Scheme 2 Synthetic route to methyl ether analogues 25 and 26. Reagents and conditions (a) K 2CO3, BnBr, DMF; (b) NaH, MeI, THF; (c) Pd/C, H2, THF

of the C3-phenolic group in naltrexone. As expected,
conversion of the phenol to the methyl ether 7 [22] or its
removal (8) [23] resulted in a complete loss of antagonist
activity (IC50 > 10,000 nM). These results suggested that
the C3-phenol was a key functional group, and it was
necessary to retain it in future analogues.
We next sought to understand if modification at the
C14β-hydroxyl position could provide enhanced opioid

antagonist activity. Replacement of the C14β-hydroxy
group with a hydrogen (9) [24] resulted in a sixfold
increase in antagonist potency compared to naltrexone (IC50 = 1.51 nM vs. IC50 = 8.82 nM). However, this
modification resulted a weaker level of fentanyl antagonism (Imax = 50.2% vs. Imax = 102.7%). These results suggested that the potency of naltrexone could be enhanced
through additional structural modification, but the

Hedrick et al. J Biomed Sci

(2021) 28:62

Page 8 of 18

Scheme 3 Synthetic route to analogues 28–30. Reagents and conditions (a) K2CO3, BnBr, DMF; (b) t-BuOK, MTPPB, THF; (c) NaH, dipropyl sulfate
(39a) or allyl bromide (39b), DMF; (d) conc. HCl, MeOH

14β-hydroxy position was important to maintaining a full
level of antagonism.
Interestingly, replacement of the 14β-amide in CCAM
with a 14β-ester (10) resulted in a complete loss of antagonist activity (IC50 = 29.57 nM vs. IC50 > 10,000 nM) [25,
41]. Modification of the aromatic substituent in 10 (11,
12) [25] and replacement of the ester with an ether (15)
resulted no enhancement of antagonist activity, rather
an increase in agonist activity. Despite its high lipophilicity, ether 15 [27] was found to be inactive as an
antagonist and to be an extremely potent MOR agonist
(EC50 = 0.38 nM) [27]. Further increasing lipophilicity by
replacement of the phenyl ring in 15 with a cyclohexyl
group (16) also had no effect on antagonizing fentanyl
but did decrease MOR agonist activity (EC50 = 1.89 nM).
Removal of the alkene of 12 (13) [26] decreased agonist activity (EC50 = 16.68 nM) with no observable level
of antagonism. Thinking that the phenyl ring might
be responsible for the weak level of antagonist activity, we replaced it with a hydrogen atom (14). To our
delight, this modification resulted in an increase in
antagonist activity (IC50 = 4.22 nM). We were excited
to see that this change also resulted in a high degree
of antagonism (Imax = 115.2%). In agreement with
a previous report, we found that alkylation of the
14β-hydroxy group of naltrexone with a methyl group
(17) [28] and ethyl group (19) [28] were well tolerated
(17: IC50 = 13.26 nM and 19: IC50 = 3.97 nM, respectively). In contrast to previous literature, however, we
found that a benzyl group (18) [29] decreased MOR
antagonist activity approximately fourfold compared
to naltrexone (IC50 = 38.95 nM vs. IC50 = 8.82 nM)
[29]. Homologation of the ethyl group to propyl (20)

resulted in an approximately threefold increase in
activity compared to naltrexone 
(IC50 = 2.55 nM vs.
IC50 = 8.82 nM). Conversion of the propyl group to an
allyl group (21) was well tolerated (IC50 = 2.58 nM).
Interestingly, dihydroxylation of the allyl group in 21
(22) only slightly decreased activity (IC50 = 6.49 nM vs
IC50 = 2.58 nM) despite significantly decreasing logP
(22: logP = 0.60 vs. 21: logP = 2.60). This further suggests that lipophilicity is not an essential characteristic
in antagonizing fentanyl.
We next chose to evaluate the role of the C6-keto group
in naltrexone. Previous structure–activity relationships
suggested that the replacement of the C-6 carbonyl in
naltrexone by a methylene group would increase opioid
antagonism [30]. As expected, nalmefene (5) was found
to be approximately fourfold more potent than naltrexone
(IC50 = 2.13 vs. IC50 = 8.82 nM). Next, we explored the
reduction of the C6-keto group to 6α-naltrexol (23) [30]
and 6β-naltrexol (24) [31]. As expected, there was a clear
stereochemical preference [31, 42]. 6β-Naltrexol (24) was
found to be approximately fourfold more potent than
6α-naltrexol (23) (IC50 = 5.85 nM vs. IC50 = 20.83 nM).
In addition, 6β-naltrexol (24) was found to be slightly
more potent than naltrexone (
IC50 = 5.85 nM vs.
IC50 = 8.82 nM). This later result was not surprising given
that 24 is an active metabolite of naltrexone [43]. Interestingly, methylation of the 6α-alcohol of 23 (25) or the
6β-alcohol of 24 (26) resulted in the retention of antagonist activity (IC50 = 18.59 nM vs. IC50 = 20.83 nM and
IC50 = 4.52 nM vs. IC50 = 5.85 nM, respectively). Finally,
we explored the removal of the C6-keto of naltrexone (27) [32]. This modification was also well tolerated
(IC50 = 8.83 nM vs. IC50 = 8.82 nM).
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R4

1.75

3.95

3.80

1.86

1.49

1.49

0.84

0.84

1.95

0.60

2.60

2.76

2.23

3.61

1.89

LogPa

4.78

4.55

4.71

4.71

4.77

4.77

4.43

4.43

4.72

3.79

4.95

4.95

5.04

4.31

5.12

CNS MPOa

3.58 ± 1.28 (115.90 ± 8.44)

2.06 ± 0.53 (86.70 ± 5.46)

2.03 ± 0.96 (100.42 ± 18.87)

8.83 ± 3.52 (121.83 ± 5.64)

4.52 ± 1.62 (99.67 ± 7.40)

18.59 ± 5.87 (85.54 ± 5.14)

5.85 ± 2.03 (110.63 ± 6.30)

20.83 ± 9.92 (69.00 ± 9.72)

6.49 ± 1.49 (149.78 ± 15.31)
2.13 ± 0.20 (128.85 ± 7.09)

2.58 ± 0.75 (96.84 ± 5.49)

2.55 ± 0.94 (94.95 ± 15.00)

3.97 ± 1.65 (89.24 ± 5.87)

38.95 ± 15.76 (102.54 ± 26.42)

13.26 ± 6.29 (71.74 ± 12.10)

MOR antagonism
IC50 (nM)b,c
(Imax)d

> 10,000

1.21 ± 0.44
(16.99 ± 3.50)

0.34 ± 0.15
(38.30 ± 7.02)

0.88 ± 0.43
(31.69 ± 3.69)

0.88 ± 0.43
(39.02 ± 5.62)

1.86 ± 0.39
(58.16 ± 4.45)

0.94 ± 0.35
(26.88 ± 4.74)

2.22 ± 1.04
(49.31 ± 11.57)

> 10,000

> 10,000

0.72 ± 0.33
(37.41 ± 8.47)

6.57 ± 3.03
(38.72 ± 8.31)

0.44 ± 0.22
(49.66 ± 8.51)

15.38 ± 3.52
(19.98 ± 1.1)

2.99 ± 1.56
(25.31 ± 2.76)

MOR agonism
EC50 (nM)b
(% efficacy)e
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Having explored the importance of the C3-phenol, the
14β-hydroxyl group, and the C6-keto group, we investigated if combinations of structural changes were additive.
Initially, we prepared alkene 28 based on the availability of starting material and tolerance of a 14β-O-allyl
group. The combination was well-tolerated and a potent
antagonist was identified (IC50 = 2.03 nM). Given this
positive result, we also synthesized alkene 29 due to the
high activity of 20 (IC50 = 2.55 nM). As expected, 29 was
found to be a highly potent antagonist (IC50 = 2.06 nM).
Introduction of the 6-methylene to 22 (30) also increased
antagonist activity (IC50 = 3.58 nM vs. IC50 = 6.49 nM),
however, with a reduction in the degree of antagonism
(Imax = 115.9% vs I max = 149.8%).
Additional Schild analyses were conducted on naltrexone, 29, and 30, using a full dose–response curve of fentanyl in the absence or presence of three concentrations
of test compounds. The Schild slopes of all three compounds were determined to not significantly deviate from
1, indicating competitive antagonism. The 
pA2 values
(the concentrations of antagonist required to have a twofold increase in the concentration of agonist to produce
a selected effect) of analogues 29 and 30 were found to
be 10.01 and 9.77, respectively, in contrast to 9.47 for the
parent compound naltrexone, which suggested a greater
potency resulting from our design (Table 2). In addition,
the equilibrium dissociation constant (Ke) values were
also calculated. Analogues 29 and 30 were found to have
Ke values of 0.103 nM and 0.159 nM, respectively, in contrast to 0.300 nM for naltrexone. These findings are consistent with the aforementioned IC50 data and support
the utility of our in vitro assay in identifying potent MOR
antagonists.
Knowing the promiscuous nature of naltrexone, several
analogues possessing low nanomolar MOR antagonist
activity (14, 20–22, 28–30) were chosen for additional
screening at KORs and DORs (Table 3). Similar to naltrexone, most of these compounds exhibit partial KOR
agonist activity, the most potent of which being the
14β-O-allyl analogues 21 (EC50 = 0.12 nM) and 28
(EC50 = 0.14 nM). Interestingly, diol analogues 22 and
30 possess no agonist activity at KORs (EC50 > 10,000).
This is similar to their actions at MORs (EC50 > 10,000).
In contrast, activity of this series of compounds at DORs
appears to be more varied. While naltrexone exhibits weak DOR antagonism, the majority of these compounds display partial DOR agonism, the most potent of
which being analogue 29 (EC50 = 0.19 nM). Analogue 22
remains an exception, exhibiting no DOR agonist activity.
Pharmacokinetics

The pharmacokinetics of 29 were evaluated using
C57BL/6J mice. Animals were administered 1 mg/kg,
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5 mg/kg, and 2 mg/kg via IV, PO, and IP dosing routes.
Plasma concentrations were above the lower quantitation limit for 2 h following IV and PO dosing, while IP
dosing resulted in measurable concentrations for at least
6 h. Plasma concentrations were fitted with a 2-compartment model to capture the biphasic elimination of 29
(Fig. 2). The model estimated PK parameters are listed in
Table 4. The oral bioavailability of 29 was approximately
6.6% while the bioavailability following IP administration
was estimated to be near 100%. 29 was rapidly absorbed
and the Tmax occurs within the first 10 min of PO and IP
administration (Fig. 3A, Table 5). The plasma half-life of
29 was estimated to ~ 0.6–1 h. Assessment of brain biodistribution demonstrated ample 29 distribution into the
brain with a T
 max of approximately 20 min. Subsequently,
brain concentrations surpass plasma concentrations and
the apparent terminal half-life in the brain is ~ 80 min
as compared to 55 min in plasma (Fig. 3B, Table 5). This
high partition into brain suggests that there is ample free
concentration of 29 in plasma and that the compound
binds more preferentially to brain tissue components
than it does to plasma proteins. Attempts to model the
brain penetration along with the plasma concentrations
were not successful, but based on the difference in apparent half-life, best fitting would likely be achieved using
a saturable redistribution model. This may be related to
29 tissue binding and prolonged partition into the brain
tissue. The estimated partition coefficient, Kp,brain, using
NCA estimates of AUC (Fig. 3B, Table 5) was 1.6.
Antagonism by 29 of oxycodone‑induced antinociception

As expected based on prior studies, oxycodone (5.6 mg/
kg), 30 min after vehicle pretreatment, resulted in a nearmaximal antinociceptive effect (Fig. 4). The peak effects
of oxycodone were observed 15 min after injection. Different doses of compound 29 were administered as a
30-min pretreatment to oxycodone (5.6 mg/kg). Compound 29 (0.01–0.1 mg/kg) caused a dose-dependent
prevention of oxycodone-induced antinociception. The
larger pretreatment dose of 29 (0.1 mg/kg) caused a complete prevention of oxycodone-induced effects. A 2-Way
repeated measures ANOVA (29 dose × time post-oxycodone) yielded a significant main effect of 29 dose (F (3,
21) = 7.263; p = 0.0016), a main effect of time post-oxycodone (F (3, 21) = 11.72; p = 0.0001), and their interaction
F (9, 63) = 2.126; p = 0.04.
We then examined the time course of antagonism by
29 of oxycodone-induced antinociception (Fig. 5). The
largest dose of 29 (0.1 mg/kg, or vehicle) was administered at different times (15, 30, 120, 240 min and 24 h)
prior to oxycodone (5.6 kg). At each pretreatment time
other than 24 h, 29 was able to significantly prevent the
peak antinociceptive effects of oxycodone (i.e. measured
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15 min after oxycodone injection). A 2-Way mixed effects
ANOVA (29 or vehicle PT, by PT time) was significant
for the main effect of 29 or vehicle PT (F (1, 32) = 116.1;
p < 0.0001). There was also a main effect of PT time (F
(4, 32) = 4.25; p = 0.007) and an interaction between PT
injection and time (F(4, 32) = 9.37; p < 0.0001). Sidak’s
post hoc tests show that 29 PT differed from vehicle PT at 15, 30, 120 and 240 min, but not 24 h prior to
oxycodone.
Antagonism by 29 of locomotor deficits caused by the KOR
agonist U50,488

These studies were designed to examine the in vivo selectivity of 29 as a MOR-antagonist, as opposed to a KORantagonist. As expected based on recent studies [36],
U50,488 (10 mg/kg; 30 min after vehicle PT) caused
a robust decrease in locomotor activity over 90 min
(Fig. 6). PT with 29 (0.1 mg/kg, compared to vehicle) did
not cause any apparent blockade of the locomotor effects
of U50,488 (10 mg/kg). Thus, a 2-way repeated measures
ANOVA (29 or vehicle PT by time bin) was not significant for the main effect of 29 or vehicle PT, or its interaction with time bin (not shown). There was a main effect of
time bin (F (5, 35) = 26.02; p < 0.0001). However, pretreatment with a tenfold larger dose of 29 (1 mg/kg, compared
to vehicle) did block the locomotor depressant effects of
U50,488 (10 mg/kg). Thus, a 2-way repeated measures
ANOVA (29 or vehicle PT by time bin) was significant
for the main effect of 29 or vehicle PT (F (1, 7) = 6.14;
p = 0.042); there was no significant interaction between
29 PT and time bin (not shown). There was a main effect
of time bin (F (5, 35) = 11.14; p < 0.0001). In separate control studies, this larger dose of 29 (1 mg/kg) alone did not
cause significant effects on locomotor activity, compared
to a vehicle injection (not shown).

Discussion
Clinical studies and case reports have indicated that overdoses from fentanyl (mediated by respiratory depression)
frequently require multiple naloxone administrations due
to the shorter duration of action of naloxone than that
of fentanyl [9]. Additionally, fentanyl can result in chest
wall rigidity, which further interferes with breathing and
exacerbates the risk of mortality [44]. Taken together, this
suggests that there is a need for the development of new
fentanyl overdose treatments.
To address this need, we initially sought to develop
an in vitro functional assay capable of identifying effective synthetic opioid rescue agents. Given that the rescue effects of naloxone are likely due to its antagonism
at MORs, we decided to adapt a commercially available
Eurofins DiscoverX H
 itHunter® cAMP Assay [33, 45,
46]. First, we elected to evaluate the ability of test ligands

Page 12 of 18

to antagonize an 
EC90 concentration of fentanyl. Our
rationale was based on attempting to find compounds
that would provide maximal protection against fentanyl’s
effects. Second, we chose to use a relatively short incubation time (15 min) to help identify rapidly acting synthetic opioid rescue agents. To more optimally assist in
an overdose or chemical attack situation with fentanyl or
other synthetic opioid, a rescue agent is needed that has
a rapid onset of action. While this property would ultimately need to be characterized in vivo, using a short
incubation time might assist in identifying such agents in
a more rapid manner. Third, this assay uses no radioactivity and is more environmentally friendly than previously
described radioactive methods using the [35S]GTPγS
assay [47, 48]. Finally, we envisioned that the assay results
would be obtained with high throughput to help direct
our synthetic efforts.
With a viable assay in hand, we focused on synthesizing and evaluating analogues of naltrexone. This was
based on previous reports which showed that naltrexone had enhanced potency compared to naloxone and is
available from commercial sources [30]. Naltrexone has
previously served as the starting point for the development of selective opioid receptor probes naltrindole and
nor-binaltorphimine (nor-BNI) [49–51]. We assume that
the rescue effects of naloxone is likely due to antagonizing the action of 1 at MORs [52]. However, since naloxone is a non-selective antagonist at opioid receptors [53],
actions at δ opioid receptors (DORs) and κ opioid receptors (KORs) were not disregarded.
Having selected a starting point for chemical synthesis, we prepared a series of analogues modified in
three positions: (1) the C3-phenol; (2) the 14β-hydroxyl
group; and (3) the C6-keto group. These positions were
selected due to synthetic tractability and potential to
alter the pharmacokinetic properties. In addition, several analogues of naltrexone modified at these positions
have been prepared previously. The structure–activity
relationships from these previous investigations were
expected to provide valuable insights in the design of
an enhanced synthetic opioid rescue agent [53, 54].
According to previous literature, the C3-phenol is an
important feature of the morphinan pharmacophore,
participating in a critical H-bond interaction at opioid
receptors [55]. To verify this hypothesis, analogues 7
and 8 (possessing C3-OMe and C3-H, respectively)
were synthesized and evaluated in vitro. As expected,
both analogues resulted in a complete loss of antagonist
activity (IC50 > 10,000 nM), supporting the hypothesis
of the key phenol interaction. Further analogues were
designed to retain this feature.
Several analogues of naltrexone possessing various modifications to the 14β-hydroxyl group have
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Table 2 Schild analysis and Ke values of antagonism of test
compounds against fentanyl to MORs by cAMP functional assay
Cmpd

Slope ± SEM

4b

1.12 ± 0.14

29
30

pA2 ± SEM

1.04 ± 0.12
1.22 ± 0.14

Ke (nM) ± SEM

9.47 ± 0.13

0.300 ± 0.097

9.77 ± 0.14

0.159 ± 0.047

10.01 ± 0.18

0.103 ± 0.030

Values are expressed as the mean ± SEM of at least three independent
measurements

previously been reported [25, 27, 56]. Of note, CCAM
displays increasingly potent antagonist activity with
a longer duration of action compared to naltrexone.
Other 14β analogues, however, have resulted in a significant loss in antagonist activity or even a complete
“switch” from antagonist to agonist activity. Taken
together, this data suggests that modification of the
14β-hydroxyl group has the ability to alter the potency
and pharmacokinetic properties of naltrexone.
After making an initial series of MOR agonists (10–
13, 15, 16), truncation of the phenyl ring at the 14β
position led to a series of analogues possessing potent
MOR antagonist activity (14, 19 – 22). Of these, the
14β-O-propyl (20) and 14β-O-allyl (21) analogues displayed the lowest IC50 values (2.55 nM and 2.58 nM,
respectively), providing the identification of our first
lead compounds.
Several modifications to the C6-ketone have also
been reported to alter the activity of naltrexone. Of
particular interest, substitution to the C6-alkene

Fig. 2 Schematic depiction of the two-compartment
pharmacokinetic model fitted to the 29 plasma concentrations. The
intravenous dose was administered in the plasma compartment
(AIV). Oral and intraperitoneal doses (APO and API, respectively) were
administered in absorption compartments

Table 4 Pharmacokinetic parameter estimates of 29 plasma
concentrations obtained using the PK model depicted in Fig. 2
Parameter

Estimate

V

5.36

CL

12.13

Units

Standard error

CV%

L/kg

2.91

L/h/kg

2.02

16.7

7.91

1/h

6.18

78.1

V2

6.07

L/kg

1.55

25.5

CL2

10.44

L/h/kg

4.25

40.7

Fpo

6.6

%

1.5

23.3

Ka,ip

7.53

1/h

4.23

Ka,po

99.5

FIP

%

17.1

54.2

56.2
17.2

Table 3 Evaluation of functional activity at KORs and DORs using Eurofins DiscoverX H
 itHunter® cAMP Assay
Cmpd

4b
14
20
21
22
28
29
30
nor-BNI
Salvinorin A

KOR antagonism
IC50 (nM)a,b
(Imax)c
5.53 ± 1.02 (41.31 ± 6.83)

8.15 ± 1.10 (49.27 ± 11.54)

8.70 ± 1.89 (46.68 ± 2.95)

10.68 ± 4.48 (62.72 ± 18.41)

33.74 ± 3.77 (84.97 ± 6.39)

8.54 ± 3.54 (47.32 ± 12.19)

4.49 ± 2.02 (46.84 ± 16.34)

8.75 ± 2.05 (89.12 ± 0.69)

2.10 ± 0.64 (98.54 ± 2.47)

NT

U50488H
Naltrindole

NT

SNC-80

NT

a
b

KOR agonism
EC50 (nM)a
(% efficacy)d
0.64 ± 0.32 (56.46 ± 7.15)

1.56 ± 0.69 (58.71 ± 5.77)

0.67 ± 0.39 (39.11 ± 4.70)

0.12 ± 0.03 (41.17 ± 8.81)

> 10,000

0.14 ± 0.04 (44.09 ± 8.43)

0.43 ± 0.18 (59.08 ± 8.54)

> 10,000

DOR antagonism
IC50 (nM)a,b
(Imax)c
177.16 ± 48.90 (99.57 ± 1.93)

> 10,000

4.06 ± 2.36 (29.48 ± 5.94)

> 10,000

368.31 ± 136.17 (89.22 ± 4.30)

> 10,000
> 10,000

48.58 ± 24.06 (49.76 ± 1.50)

DOR agonism
EC50 (nM)a
(% efficacy)d
> 10,000
2.09 ± 0.80 (47.42 ± 2.58)

1.04 ± 0.35 (48.05 ± 1.87)

2.28 ± 0.72 (45.47 ± 2.38)

> 10,000

0.72 ± 0.22 (48.92 ± 3.66)

0.19 ± 0.09 (54.96 ± 3.44)

0.86 ± 0.33 (32.98 ± 3.21)

NT

NT

NT

0.026 ± 0.005 (98.66 ± 0.85)

NT

NT

NT

0.51 ± 0.17 (100.14 ± 6.20)

NT

0.18 ± 0.06 (98.99 ± 0.83)
NT

Values are expressed as the mean ± SEM of at least three independent measurements

NT

Antagonist potency (IC50) determined versus EC90 of U50,488H for KORs and EC50 of SNC-80 for DORs

c

Degree of antagonism (Imax) normalized to nor-BNI for KORs and 4b for DORs

d

Agonist efficacy expressed as percent stimulation

1.27 ± 0.22 (76.33 ± 1.38)
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Fig. 3 Pharmacokinetic data following 29 administration by multiple routes. Plasma concentrations by IV, PO, and IP routes (A) and comparative
plasma and brain concentrations following IP dosing (B)

Table 5 Descriptive pharmacokinetic parameters of 29 exposure
Dosing route/dose

AUC (nM-h)

Tmax (h)

Apparent
half-life, t½
(h)
0.58

IV, 2 mg/kg

207

0.08

PO, 5 mg/kg

64

0.1

0.99

IP, 2 mg/kg
Plasma

397

0.12

0.94

IP, 2 mg/kg Brain

634

0.32

1.34

provides nalmefene (5), possessing a fourfold increase
in potency compared to naltrexone (IC50 = 2.13 nM vs
IC50 = 8.82 nM). This favorable trend led to the introduction of the C6-alkene onto the previously discovered
antagonists 20 and 21, providing the potent analogues 29
and 28, respectively. These analogues are believed to be
among the most potent MOR antagonists known to date
(IC50 = 2.06 nM and IC50 = 2.03 nM).

Fig. 4 Dose-dependence of antagonist effects of compound 29 (0.01–0.1 mg/kg, IP), administered 30 min before oxycodone (5.6 mg/kg), in the
thermal antinociception assay. X-axis: Time in minutes after oxycodone administration. Y-axis: %Maximum possible effect (%MPE)
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Fig. 5 Time course of antagonist effects of compound 29 (0.1 mg/
kg, IP), administered at different pretreatment (PT) before oxycodone
(5.6 mg/kg), in the thermal antinociception assay (n = 7–8). X-axis:
PT time for 29 before oxycodone injection. Y-axis: %Maximum
possible effect (%MPE). Data are shown at the 15-min timepoint
after oxycodone (i.e., its peak effect). Stars represent significance of
post-hoc Sidak tests

Fig. 6 Dose-dependence of antagonist effects of compound 29
(0.1 and 1.0 mg/kg), administered 30 min before U50,488 (10 mg/
kg), in the locomotor activity assay. X-axis: Time bins in minutes after
U50,488. Y-axis: Photocell beam breaks in the locomotor activity cage

As expected, analogues 28 and 29 exhibit partial KOR
agonist activity, similar to that of naltrexone. Their activity at the DOR, however, differs from naltrexone as they
display potent partial agonism and no DOR antagonism.
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This change is activity is not expected to negatively
impact the effectiveness, nor contribute harmful side
effects, of a fentanyl overdose rescue agent.
Potent analogue 29 was chosen to undergo further PK
analysis to assess its duration of action and brain distribution. We found that 29 was rapidly absorbed with a near
100% bioavailability following IP administration. Furthermore, brain concentrations of 29 surpassed plasma concentrations, suggesting ample and prolonged partition into
the brain tissue. However, 29 possesses a relatively short
plasma half-life (0.9 h) with an apparent terminal half-life
of ~ 80 min in the brain. In comparison, the terminal halflife of fentanyl is ~ 220 min, nearly 3× that of 29.
To determine the in vivo on-target effectiveness of 29,
antagonism of oxycodone-induced antinociception was
studied using the traditional hot plate assay [57]. The hot
plate assay is a widely used preclinical test of supra-spinal analgesic efficacy, possessing a high predictive value
for drugs targeting MORs [58]. Before tackling the more
complex in vivo pharmacology of fentanyl and fentanyl
analogues [44], antagonism of oxycodone-induced antinociception was selected as an initial proof of concept to
verify the in vivo actions of our new opioid rescue agents.
Results from these studies show that 29 is dose-dependently (0.01–0.1 mg/kg) and fully effective in preventing
antinociception caused by the frequently abused MOR
agonist, oxycodone. In these studies, 29 also showed
relatively fast onset of antagonist action after IP injection (within 15 min) and a duration of action of at least
240 min, but less than 24 h. This profile is desirable in
principle, as sufficient duration of action is important to
prevent the effects of high potency abused MOR agonists
which are currently causing considerable morbidity [59].
Therefore, the duration of MOR-antagonist action of 29
appears to be more extended than that indicated by PK
analyses above.
Other in vivo studies also show that 29 has relative
selectivity as an antagonist of MOR- over KOR-mediated
effects. Specifically, the dose of 29 that is fully effective in
preventing oxycodone-induced antinociception (0.1 mg/
kg) was ineffective against locomotor deficits caused by
the KOR agonist U50,488. However, a tenfold greater
dose of 29 (1 mg/kg) was able to prevent locomotor deficits caused by this KOR agonist. Overall, this shows that
doses of 29 could be titrated in vivo to block only MOR
mediated effects, as opposed to both MOR and KOR
mediated effects. This profile could be examined in further translational models in the future.

Conclusions
To combat the ever-increasing rate of death by opioid overdose (due to recreational use and/or chemical
warfare situations), this research aims at identifying a

Hedrick et al. J Biomed Sci

(2021) 28:62

synthetic opioid rescue agent superior to naloxone. Our
studies began with the development of an in vitro functional assay capable of identifying ligands with the ability to antagonize an E
 C90 concentration of fentanyl. This
assay, with its high fentanyl challenge dose and short
pretreatment time, better represents an overdose situation, increasing the likelihood of identifying effective
rescue agents. Indeed, following the design and synthesis of novel naltrexone analogues, in vitro analysis using
our modified functional assay led to the identification of
a series of potent MOR antagonists, including the highly
potent analogue 29. Further in vivo studies highlight the
quick onset of action and ample brain distribution of this
compound.
Even though the results from the hot plate assay suggest a relatively long duration of action, the PK analysis
of 29 reveals its terminal half-life to only be ~ 80 min,
roughly one-third that of fentanyl’s terminal half-life. This
difference in half-life (and possibly duration of action)
poses a potential problem, as the chance of renarcotization remains possible. However, the duration of MOR
antagonist action of 29 observed in vivo herein is at least
240 min, giving rise to the possibility that the pharmacodynamic duration of this compound is longer than that
expected based on systemic PK data. In order to avoid
renarcotization and the need for repeated administration, the duration of action of an improved rescue agent
is desired to be greater than that of fentanyl. Therefore,
future studies are currently underway aimed at modifying the structure of 29 to increase its half-life and duration of action, while maintaining its potency profile. Such
an agent has the potential to become a clinical candidate
for the reversal of synthetic opioid overdose.
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